We recently showed the good-prognosis value of high CSPG4 expression in a series of 309 GIST [45], whereas higher expression was associated with poorer prognosis in melanoma [46], glioblastoma [47], breast cancer [48], head and neck squamous cell carcinomas [49], and hepatocellular carcinoma [50]. Here, CSPG4 is linked to glioblastoma.